SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL
Open Access
- 23 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 6009-6013
Abstract
While venetoclax (VEN)-based regimens are highly effective for patients with chronic lymphocytic leukemia (CLL), initiation is complex, due to the requirement of a 5-week dose ramp-up used to mitigate the risk of tumor lysis syndrome (TLS). We report the results of the first prospective study of VEN initiation using an accelerated inpatient dose ramp-up in CLL. Forty patients were treated, including 15 (37.5%) with relapsed or refractory disease and 13 (32.5%) with medium (27.5%, n=11) or high (5%, n=2) TLS risk at enrollment. All except one (97.5%) received obinutuzumab in combination with VEN. All patients completed an accelerated daily VEN ramp-up from 20 mg to 400 mg in the inpatient setting. None had clinical TLS. One (2.5%) patient with Bruton tyrosine kinase inhibitor-refractory CLL and high TLS risk developed laboratory TLS after the 200 mg dose of VEN, which normalized within a day with a 1-day dose hold and supportive care. The median inpatient time was 7 days. In intent-to-treat analyses of efficacy at 3 months, the overall response rate was 78.0%. Our data support the feasibility of accelerated VEN ramp-up in select patients in experienced centers and warrant further exploration of this approach in broader clinical settings. NCT04843904Keywords
This publication has 12 references indexed in Scilit:
- Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 studyMed, 2025
- A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemiaAmerican Journal of Hematology, 2021
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2019
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLBlood, 2018
- Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation projectCytometry Part B: Clinical Cytometry, 2018
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004